Date of Award
Ph.D. in Pharmaceutical Sciences
Pharmaceutics and Drug Delivery
Michael A. Repka
The Chapter II focuses on formulation of an optimized and robust amphotericin B ocular formulation with prolonged precorneal residence and ocular tissue concentration at par or superior to the marketed preparations. Additionally, demonstrating stability of amphotericin B formulations in presence of preservative in comparison to marketed preparation, making it an ideal choice of formulation for multi-dosing. As mentioned earlier, we optimized PEGylated nanostructured lipid carriers (PEG-NLC-AmB) for ocular delivery of amphotericin B. The formulations could be autoclaved with at least one-month stability and in vivo ocular biodistribution was statistically insignificantly different compared to AmBisome®. To accomplish the aim, strategies such as mucoadhesion and/or viscosity enhancement were investigated. In this regard, PEG-NLC-AmB entrapped in ion triggered hydrogels using gellan gum (mucoadhesive) and chitosan (mucoadhesive and permeation enhancer) coated PEG-NLC-AmB were formulated and characterized.
Lakhani, Prit Manish, "PEGylated Nanostructured Lipid Carries for Amphotericin B Ocular Delivery" (2019). Electronic Theses and Dissertations. 1634.
Available for download on Wednesday, September 22, 2021